Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Akeso, Inc. is conducting a multicenter, open-label, Phase II study ...

“The results of our analysis showed that overall, patients with SCLC who survived to receive 3L treatment are a select group ...

Genelux Corp. (($GNLX)) announced an update on their ongoing clinical study. Genelux Corp. is currently conducting a Phase 2 clinical study titled ...

In this video, Charu Aggarwal, MD, MPH, the Leslye M. Heisler Professor for Lung Cancer Excellence at University of ...

Modest absolute reduction in use observed, which increased during peak of shortage; no difference seen in mortality during shortage. (HealthDay News) — The platinum chemotherapy shortage, first ...

OptiTROP-Lung04 study showed sac-TMT improved survival in pts with EGFR-mutated NSCLC who had progressed on EGFR-targeted TKIs, compared with chemotherapy.

A 2023 shortage of the generic platinum-based chemotherapy drugs cisplatin and carboplatin had no effect on cancer mortality rates, according to a study published Dec. 3 in the Journal of the National ...

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results ...

Platinum-associated adverse events were more likely in patients with impaired kidney function assessed by serum creatinine and cystatin C -- warranting judicious adjustment of platinum chemotherapy ...

Neoadjuvant immunochemotherapy shows higher pCR and MPR rates compared to chemotherapy alone in LS-SCLC patients, suggesting enhanced tumor regression before surgery. Propensity score matching ...